Jeffrey Miller's profile

Jeffrey Miller

Principal Investigator

University of Minnesota

I'm working on

7 months ago

Cell therapy, Immuno-oncology, NK engineering

About

Jeffrey Miller advances off-the-shelf NK cell therapies and multispecific engager biologics, including iPSC-derived NK platforms and IL-15 modulators. Early clinical studies in lymphoma and HIV. NCI P01/R35 support; issued patent on NK-engaging compounds.

Partnering listings

Learn more

University of Minnesota

Tri-specific killer engagers (TriKEs) for targeted cancer immunotherapy

Tri-specific Killer Engagers (TriKEs) enhance NK cell targeting of solid tumors by binding CD16 and B7-H3 antigens. Combined with IL-15, they boost T cell response, overcoming tumor-induced immune exhaustion. Validated i...

TechnologyIn marketUniversity

Jeffrey Miller

Principal Investigator

University of Minnesota

Work experience

University of Minnesota

Principal Investigator

Top industry applications

Oncology & cancer therapeutics

Open to opportunities in

Cell BiologyCell TherapyImmunotherapy

Last updated Feb 2026